Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | M Pegram E Hamilton A R Tan A M Storniolo N Elgeioushi S Marshall S Abdullah M Patel | ||||||||||||
Title | Phase 1 study of bispecific HER2 antibody-drug conjugate MEDI4276 in patients with advanced HER2-positive breast or gastric cancer | ||||||||||||
|
|||||||||||||
URL | https://academic.oup.com/annonc/article/29/suppl_3/mdy048.005/4917517 | ||||||||||||
Abstract Text | Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MEDI4276 | MEDI-4276 | HER2 (ERBB2) Antibody 72 | MEDI4276 is a bispecific antibody against two separate epitopes of Erbb2 (Her2) in conjugation with a microtubule inhibitor, which may target Erbb2 (Her2)-positive tumor cells (Annals of Oncology, Volume 29, Issue suppl_3, 1 March 2018, abstract 470). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|